MetaCap

Dr. Reddy's Laboratories (RDY) vs Spyre Therapeutics (SYRE)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Spyre Therapeutics (SYRE) has outperformed Dr. Reddy's Laboratories (RDY) over the past year, gaining 285.3% versus a gain of 7.0%. Over five years, RDY leads with a +18.2% price change compared with -42.0% for SYRE. Dr. Reddy's Laboratories is the larger company by market cap ($12.41 billion vs $8.88 billion), about 1.4 times the size.

Dr. Reddy's Laboratories pays a dividend yielding 53.73%, while Spyre Therapeutics does not currently pay one.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

RDY+7.05%SYRE+285.28%
+368%+166%-37%
Nov 21, 20251 yearNov 20, 2026
RDY+19.43%SYRE-44.03%
+41%-32%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

RDY versus SYRE key metrics
MetricRDYSYRE
Share price$14.89$93.47
Market cap$12.41B$8.88B
1-day change+0.40%-4.26%
YTD return+6.05%+185.32%
1-year return+7.05%+285.28%
5-year return+18.19%-42.03%
P/E ratio (TTM)41.36—
Forward P/E22.47—
EPS (TTM)$0.36$-2.49
Dividend yield53.73%0.00%
Annual dividend$8.00$0.00
Revenue (latest FY)$3.81B$0
Revenue growth (YoY)+13.76%—
Net income (latest FY)$663.00M$-155.20M
Gross margin58.51%—
Operating margin22.09%—
Net margin17.40%—
52-week high$15.67$110.64
52-week low$11.36$24.58
Distance from 52-week high-4.98%-15.52%
Analyst consensusbuystrong_buy
Avg. price target upside+0.20%+32.52%
Average volume2.85M1.26M
Shares outstanding833.66M94.97M
Employees27,527130
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • SYRE has outperformed RDY by 278.2 percentage points over the past year.
  • Dr. Reddy's Laboratories offers a meaningfully higher dividend yield (53.73% vs 0.00%).

About Dr. Reddy's Laboratories

RDY stock →

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally.

Health Care · Biotechnology: Pharmaceutical Preparations · 27,527 employees

About Spyre Therapeutics

SYRE stock →

Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 – anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A).

Health Care · Biotechnology: Pharmaceutical Preparations · 130 employees

RDY vs SYRE FAQ

Which is bigger, Dr. Reddy's Laboratories or Spyre Therapeutics?

Dr. Reddy's Laboratories (RDY) is larger, with a market capitalization of $12.41B compared with $8.88B for Spyre Therapeutics (SYRE).

Which stock has performed better over the past year, RDY or SYRE?

SYRE returned +285.28% over the past 12 months, compared with +7.05% for RDY (price return, excluding dividends). Past performance does not predict future results.

Which pays a higher dividend, Dr. Reddy's Laboratories or Spyre Therapeutics?

Dr. Reddy's Laboratories pays a dividend yielding 53.73%, while Spyre Therapeutics does not currently pay a regular dividend.

Are Dr. Reddy's Laboratories and Spyre Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons